The main pharmacological action is to relax vascular smooth muscle. Nitroglycerin releases nitric oxide (NO), which is the same as endothelial relaxing factor, activating guanylate cyclase, increasing cyclic guanosine monophosphate (cGMP) in smooth muscle and other tissues, leading to dephosphorylation of myosin light chain, regulating the contractile state of smooth muscle, and causing vasodilation.

Estrogen drugs. They can cause endometrial hyperplasia, enhance uterine smooth muscle contraction, and promote breast development and hyperplasia. Large doses inhibit the release of prolactin, counteract the effects of androgens, and increase calcium deposition in bones.

Estrogen drugs. They can cause endometrial hyperplasia, enhance uterine smooth muscle contraction, and promote breast development and hyperplasia. Large doses inhibit the release of prolactin, counteract the effects of androgens, and increase calcium deposition in bones.

Estrogen drugs. They can cause endometrial hyperplasia, enhance uterine smooth muscle contraction, and promote breast development and hyperplasia. Large doses inhibit the release of prolactin, counteract the effects of androgens, and increase calcium deposition in bones.

It has anti-thrombotic effect. It inhibits platelet aggregation and release. Possible mechanisms include: (1) inhibiting platelet uptake of adenosine; (2) inhibiting phosphodiesterase to increase cyclic adenosine monophosphate (cAMP) in platelets; (3) inhibiting the formation of thromboxane A2 (TXA2); (4) enhancing endogenous PGI2. It has a dilating effect on blood vessels, can reduce systemic circulation and coronary vascular resistance, and increase coronary blood flow.